Kenneth D Westover

List of Publications by Year
in descending order

129	8,065	70961 41	51492 86
papers	citations	h-index	g-index

142	142	142	11887
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consolidative Radiotherapy for Limited Metastatic Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2018, 4, e173501.	3.4	755
2	Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition. Cell, 2012, 150, 987-1001.	13.5	723
3	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Molecular Cancer Research, 2015, 13, 1325-1335.	1.5	503
4	Structural Basis of Transcription: Role of the Trigger Loop in Substrate Specificity and Catalysis. Cell, 2006, 127, 941-954.	13.5	421
5	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nature Chemical Biology, 2016, 12, 452-458.	3.9	389
6	Structural Basis of Transcription: An RNA Polymerase II-TFIIB Cocrystal at 4.5 Angstroms. Science, 2004, 303, 983-988.	6.0	307
7	Therapeutic Targeting of Oncogenic Kâ€Ras by a Covalent Catalytic Site Inhibitor. Angewandte Chemie - International Edition, 2014, 53, 199-204.	7.2	262
8	Structural Basis of Transcription. Cell, 2004, 119, 481-489.	13.5	248
9	Structural Basis of Transcription: Separation of RNA from DNA by RNA Polymerase II. Science, 2004, 303, 1014-1016.	6.0	231
10	Structural Basis of Transcription: Backtracked RNA Polymerase II at 3.4 Angstrom Resolution. Science, 2009, 324, 1203-1206.	6.0	225
11	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	13.5	220
12	In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8895-8900.	3.3	193
13	Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. Cell Chemical Biology, 2020, 27, 19-31.e6.	2.5	182
14	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. Cancer Research, 2013, 73, 2574-2586.	0.4	170
15	Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology, 2014, 10, 1006-1012.	3.9	161
16	Neutrophilâ€“Lymphocyte and Plateletâ€“Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 280-285.	0.5	154
17	Tissue-Specific Oncogenic Activity of KRASA146T. Cancer Discovery, 2019, 9, 738-755.	7.7	127
18	Structural basis of eukaryotic gene transcription. FEBS Letters, 2005, 579, 899-903.	1.3	120

#	Article	IF	Citations
19	Data publication with the structural biology data grid supports live analysis. Nature Communications, 2016, 7, 10882.	5.8	113
20	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology, 2017, 24, 1005-1016.e3.	2.5	109
21	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-Î± Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology, 2017, 24, 1029-1039.e7.	2.5	104
22	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology, 2019, 26, 792-803.e10.	2.5	103
23	Direct Targeting of Î²-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/Î²-Catenin Signaling. Cell Reports, 2016, 16, 28-36.	2.9	98
24	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. Journal of Biological Chemistry, 2012, 287, 9742-9752.	1.6	89
25	Discovery of a selective inhibitor of doublecortin like kinase 1. Nature Chemical Biology, 2020, 16, 635-643.	3.9	84
26	Mechanism of Rab Geranylgeranylation:Â Formation of the Catalytic Ternary Complexâ€. Biochemistry, 1998, 37, 12559-12568.	1.2	81
27	Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. American Journal of Veterinary Research, 2004, 65, 810-818.	0.3	75
28	Nonsteroidal Anti-Inflammatory Drugs, Acetaminophen, Cyclooxygenase 2, and Fever. Clinical Infectious Diseases, 2000, 31, S211-S218.	2.9	70
29	Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. Journal of Biological Chemistry, 2017, 292, 112-120.	1.6	70
30	Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17361-17364.	3.3	66
31	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 72-81.	0.4	62
32	Discovery of Type II Inhibitors of TGFÎ²-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2). Journal of Medicinal Chemistry, 2015, 58, 183-196.	2.9	62
33	Proton SBRT for Medically Inoperable Stage I NSCLC. Journal of Thoracic Oncology, 2012, 7, 1021-1025.	0.5	61
34	Covalent Guanosine Mimetic Inhibitors of G12C KRAS. ACS Medicinal Chemistry Letters, 2017, 8, 61-66.	1.3	59
35	Development of small molecules targeting the pseudokinase Her3. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3382-3389.	1.0	53
36	Treatment of Non-Small Cell Lung Cancer Patients With Proton Beam-Based Stereotactic Body Radiotherapy: Dosimetric Comparison With Photon Plans Highlights Importance of Range Uncertainty. International Journal of Radiation Oncology Biology Physics, 2012, 83, 354-361.	0.4	52

#	Article	IF	Citations
37	Radical prostatectomy vs radiation therapy and androgenâ€suppression therapy in highâ€risk prostate cancer. BJU International, 2012, 110, 1116-1121.	1.3	46
38	Genome-wide distribution of histone H4 Lysine 16 acetylation sites and their relationship to gene expression. Genome Integrity, 2013, 4, 3.	1.0	46
39	Multi-objective radiomics model for predicting distant failure in lung SBRT. Physics in Medicine and Biology, 2017, 62, 4460-4478.	1.6	46
40	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Nonâ€“Small Cell Lung Cancer and Poor Performance Status. JAMA Oncology, 2021, 7, 1497.	3.4	45
41	A structural model of a Rasâ€“Raf signalosome. Nature Structural and Molecular Biology, 2021, 28, 847-857.	3.6	44
42	Accurate real time localization tracking in a clinical environment using Bluetooth Low Energy and deep learning. PLoS ONE, 2018, 13, e0205392.	1.1	43
43	Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology, 2019, 26, 818-829.e9.	2.5	43
44	Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer. Physics in Medicine and Biology, 2018, 63, 095007.	1.6	42
45	KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. Biochemistry, 2018, 57, 324-333.	1.2	40
46	Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters. Radiotherapy and Oncology, 2016, 119, 501-504.	0.3	39
47	Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. Journal of Experimental and Clinical Cancer Research, 2021, 40, 220.	3.5	35
48	Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro-Oncology, 2020, 22, 1831-1839.	0.6	34
49	Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. Journal of Molecular Biology, 2016, 428, 4723-4735.	2.0	30
50	Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. EBioMedicine, 2019, 46, 105-118.	2.7	30
51	KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2020, 80, 3719-3731.	0.4	30
52	Stereotactic Ablative Radiotherapy (SABR) for Nonâ€“Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 845-854.	0.8	29
53	Comprehensive and EfficientHBBMutation Analysis for Detection of Î²-Hemoglobinopathies in a Pan-Ethnic Population. American Journal of Clinical Pathology, 2010, 133, 700-707.	0.4	28
54	Structure-guided development of covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 838-846.	1.4	28

#	Article	IF	Citations
55	KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. Structure, 2017, 25, 1442-1448.e3.	1.6	27
56	Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. Journal of Medicinal Chemistry, 2020, 63, 1624-1641.	2.9	27
57	GADD45Î± sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. Cell Death and Disease, 2018, 9, 524.	2.7	26
58	Three-dimensional printer-aided casting of soft, custom silicone boluses (SCSBs) for head and neck radiation therapy. Practical Radiation Oncology, 2018, 8, e167-e174.	1.1	25
59	Significance testing as perverse probabilistic reasoning. BMC Medicine, 2011, 9, 20.	2.3	24
60	Structural basis of the atypical activation mechanism of KRASV14I. Journal of Biological Chemistry, 2019, 294, 13964-13972.	1.6	24
61	A pilot study using kernelled support tensor machine for distant failure prediction in lung SBRT. Medical Image Analysis, 2018, 50, 106-116.	7.0	22
62	Progress on Covalent Inhibition of KRASG12C. Cancer Discovery, 2016, 6, 233-234.	7.7	21
63	A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patientsâ€"An Interim Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, E451.	0.4	19
64	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology, 2020, 27, 1229-1240.e4.	2.5	19
65	Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer. Seminars in Oncology, 2014, 41, 57-68.	0.8	18
66	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 1320-1328.	1.4	17
67	A highly selective inhibitor of interleukin-1 receptorâ€"associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. Journal of Biological Chemistry, 2020, 295, 1565-1574.	1.6	17
68	Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences, 2020, 7, 81.	1.6	17
69	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Molecular Therapy, 2022, 30, 621-631.	3.7	17
70	Rationale for RAS mutation-tailored therapies. Future Oncology, 2017, 13, 263-271.	1.1	16
71	Synthesis and Structureâ€"Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold. Journal of Medicinal Chemistry, 2020, 63, 7817-7826.	2.9	16
72	Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. Journal of Experimental and Clinical Cancer Research, 2019, 38, 165.	3.5	15

#	Article	IF	Citations
73	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS ONE, 2016, 11, e0155217.	1.1	14
74	SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. Lung Cancer, 2015, 89, 87-93.	0.9	13
75	Automated Text Message Reminders Improve Radiation Therapy Compliance. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1045-1052.	0.4	13
76	Mycotic aneurysm of the left main coronary artery producing acute coronary occlusion and purulent pericarditis. International Journal of Cardiology, 2007, 114, E81-E82.	0.8	12
77	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research, 2016, 185, 527-538.	0.7	11
78	Coordinating Tissue Regeneration Through Transforming Growth Factor-Î² Activated Kinase 1 Inactivation and Reactivation. Stem Cells, 2019, 37, 766-778.	1.4	10
79	Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Lung Cancer, 2021, 153, 73-80.	0.9	10
80	Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability. International Journal of Molecular Sciences, 2022, 23, 7095.	1.8	10
81	Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma. Bone, 2020, 139, 115517.	1.4	9
82	Dynamic surveillance of tamoxifenâ€resistance in ERâ€positive breast cancer by CAIXâ€targeted ultrasound imaging. Cancer Medicine, 2020, 9, 2414-2426.	1.3	8
83	The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biology, 2021, 19, e3001281.	2.6	7
84	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research, 2021, 81, 4685-4695.	0.4	6
85	Structural dataset for the fast-exchanging KRAS G13D. Data in Brief, 2015, 5, 572-578.	0.5	5
86	Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Scientific Reports, 2019, 9, 14258.	1.6	5
87	Contact Tracing in Healthcare Settings During the COVID-19 Pandemic Using Bluetooth Low Energy and Artificial Intelligenceâ€"A Viewpoint. Frontiers in Artificial Intelligence, 2021, 4, 666599.	2.0	5
88	GTP hydrolysis is modulated by Arg34 in the RASopathyâ€associated KRAS^{P34R}. Birth Defects Research, 2020, 112, 708-717.	0.8	4
89	Development of a realâ€time indoor location system using bluetooth low energy technology and deep learning to facilitate clinical applications. Medical Physics, 2020, 47, 3277-3285.	1.6	4
90	Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Journal of Molecular Biology, 2022, 434, 167626.	2.0	4

#	Article	IF	Citations
91	Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors Following Stereotactic Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S621.	0.4	3
92	Synthesis and Structureâ€“Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry, 2022, 238, 114433.	2.6	3
93	Structural Basis of Transcription. Cell, 2004, 119, 1055.	13.5	2
94	Predicting Distant Failure in Lung Stereotactic Body Radiation Therapy Using Multiobjective Radiomics Model. International Journal of Radiation Oncology Biology Physics, 2016, 96, S193-S194.	0.4	2
95	3D printer-assisted Soft Silicone Compensators for Electron Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E649.	0.4	2
96	Consolidative Radiotherapy for Limited Metastatic Nonâ€“Small Cell Lung Cancer: A Randomized Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1314.	0.4	2
97	ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRASâ€“ERKâ€“AP-1 T cell signaling-transcriptional axis. Nature Communications, 2022, 13, 1109.	5.8	2
98	Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry. Journal of Organic Chemistry, 2022, 87, 125-136.	1.7	2
99	Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease. International Journal of Radiation Oncology Biology Physics, 2016, 96, E527.	0.4	1
100	GTP-Competitive Inhibitors of RAS Family Members. , 2017, , 155-174.		1
101	P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, S2261.	0.5	1
102	Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay. STAR Protocols, 2021, 2, 100587.	0.5	1
103	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. Journal of Clinical Oncology, 2020, 38, e21571-e21571.	0.8	1
104	Impact of Superposition/convolution Dose Algorithm Inaccuracies in SBRT of Patients with Early Stage NSCLC: A Monte Carlo Study. International Journal of Radiation Oncology Biology Physics, 2010, 78, S792.	0.4	0
105	Should a Sentinel Node Biopsy be Performed in Patients with High Risk Breast Cancer?. International Journal of Radiation Oncology Biology Physics, 2010, 78, S256-S257.	0.4	0
106	Outcomes of Proton Beam Based SBRT in Medically Inoperable Stage I NSCLC. International Journal of Radiation Oncology Biology Physics, 2011, 81, S616-S617.	0.4	0
107	Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer?. International Journal of Breast Cancer, 2011, 2011, 1-5.	0.6	0
108	Developments in stereotactic ablative radiotherapy for the treatment of early-stage lung cancer. Lung Cancer Management, 2013, 2, 129-139.	1.5	0

#	Article	IF	Citations
109	Development and Experience With an EMR-Based Radiation Oncology Toxicity Recording Instrument (ROTOX): Benchmarking and Quality Improvement. International Journal of Radiation Oncology Biology Physics, 2014, 90, S820.	0.4	0
110	(P084) Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Tumors Greater Than 5 cm. International Journal of Radiation Oncology Biology Physics, 2017, 98, E38.	0.4	0
111	Use of Hypofractionated Radiation Therapy With Concurrent Chemotherapy in Inoperable Stage II/III Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468.	0.4	0
112	Modern Non-operative Treatment Strategies for Patients With Stage II-III Nonâ€“small Cell Lung Cancer in the United States. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468-E469.	0.4	0
113	A Support Tensor Machine Based Algorithm for Distant Failure Prediction in Lung SBRT. International Journal of Radiation Oncology Biology Physics, 2017, 99, E686-E687.	0.4	0
114	P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC. Journal of Thoracic Oncology, 2017, 12, S2304.	0.5	0
115	Patterns of Failure after 5 Fraction Stereotactic Ablative Radiation Therapy in Early Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e696.	0.4	0
116	The to and fro of Rho. Structure, 2021, 29, 507-509.	1.6	0
117	Structural basis of RNA polymerase II substrate specificity and catalysis. FASEB Journal, 2007, 21, A656.	0.2	0
118	SU-FF-T-650: Dosimetric Benefit of a Combination of Respiratory-Gating, Image-Guidance and Intensity Modulated Radiation Therapy for Pancreatic Cancer Treatment. Medical Physics, 2009, 36, 2674-2674.	1.6	0
119	SU-E-T-545: Assessing the Impact of Proton Range Uncertainties on NSCLC Lung Patients Treated with Proton Beam-Based SBRT. Medical Physics, 2011, 38, 3614-3614.	1.6	0
120	Abstract PR07: Crystal structure of K-Ras G12C bound to an active site inhibitor. , 2014, , .		0
121	Abstract LB-031: Biochemical profiling of cancer-associated KRAS mutants: clues towards an understanding of differential clinical outcomes. , 2015, , .		0
122	Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair. , 2015, , .		0
123	Abstract A178: Structure guided development of irreversible inhibitors for TAK1. , 2015, , .		0
124	Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20046-e20046.	0.8	0
125	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0
126	Abstract IA03: KRAS Q61H preferentially signals through the MAPK pathway in non-small cell lung cancer. , 2020, , .		0

#	Article	IF	Citations
127	Abstract 4017: Biochemical and biophysical characterization of a covalent inhibitor of Src kinase. , 2020, , .		0
128	Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: AÂCase Report of Lung Transplantation and Local Salvage. JTO Clinical and Research Reports, 2020, 1, 100094.	0.6	0
129	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0